



Acquisition FAQ's

- » Key Facts and History
- » Board of Directors & Management
- » Acquisition FAQ's
- » Corporate Governance
- » U.S. Healthcare Compliance Program
- » U.S. Assistance Programs
- » Partnerships
- » Supplier Diversity
- » Locations
- » Contact Us

[Home](#) » [About](#) » [Acquisition FAQ's](#)

Acquisition FAQs

Thank you for visiting Valeant's Acquisition FAQs page. Here you will find links to the most up-to-date information on our acquisitions and other major business transactions. Please visit this page often as we will continue to update the information here on a consistent basis.

Acquisition of Synergetics USA, Inc. by Valeant

Valeant Pharmaceuticals International, Inc., (NYSE: VRX) (TSX: VRX) completed its acquisition of Synergetics USA, Inc. on October 15, 2015. Synergetics will retain its name and it will become a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc.

For more information, please go [here](#) for shareholder FAQs

Acquisition of Salix Pharmaceuticals, Ltd. by Valeant

Valeant Pharmaceuticals International, Inc. (NYSE: VRX/TSX: VRX) completed its acquisition of Salix Pharmaceuticals, Ltd. on April 1, 2015.

For more information, please go [here](#) for shareholder FAQs

Acquisition of Solta Holdings Inc. by Valeant

Valeant Pharmaceuticals International, Inc., (NYSE: VRX) (TSX: VRX) completed its acquisition of Solta Medical on January 23, 2014. Solta Medical will retain its name and its product offering will be integrated into Valeant's aesthetics portfolio.

For more information, please go [here](#) for shareholder FAQs

Acquisition of Bausch + Lomb Holdings Inc. by Valeant

On August 5, 2013, Valeant Pharmaceuticals International, Inc., completed its acquisition of Bausch + Lomb. Valeant's existing ophthalmology businesses have been integrated into the Bausch + Lomb division to create a global eye health platform. The united business has a vast eye care product portfolio and a full array of innovative, late stage over-the-counter, prescription and ophthalmic surgery products in the development pipeline.

For more information, please go [here](#) for shareholder FAQs.

Petitioner InnoPharma EX 1129

IPR2015-00902

IPR2015-00903

Page 1

